Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y 12 inhibitor has been the standard of care to prevent thrombotic events in patients with acute coronary syndrome (ACS) undergoing ...

Giving statins before percutaneous coronary intervention (PCI) lowers the risk of 30-day events compared with post-PCI initiation or no or low-dose statins in patients with acute coronary syndromes ...

ORLANDO — The risk for clinical events at 30 days in a trial that enrolled a broad population with acute coronary syndrome (ACS) was not affected by administration of two 80-mg loading doses of ...

Patients with left main coronary artery disease who present with ACS fare just as well when treated with PCI as they do with CABG surgery, according to results of a new study. While ACS patients had ...

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Despite fewer bleeding events, 1-month dual antiplatelet ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Long-term ticagrelor monotherapy after ...

INDIANAPOLIS and TOKYO, Sept. 16 /PRNewswire/ -- In a Phase II study, Acute Coronary Syndrome (ACS) patients on maintenance clopidogrel/aspirin therapy who were switched to prasugrel (Efient® - either ...

Patients with acute coronary syndromes (ACS) who are at high risk for bleeding have significantly lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous ...

"This study suggests that the ARC-HBR and PRECISE-DAPT bleeding criteria can be used to risk stratify patients and guide the therapeutic selection to lower the bleeding risk. For instance, we found ...